Qli5 Therapeutics develops a new class of proteasome inhibitors.
Qli5 Therapeutics has raised $7.2M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2026.
Qli5 Therapeutics's investors include Atinum Partners, SV Investment Corp, Qurient Therapeutics, KHAN Technology Transfer Fund, DAOL Investment.
Qli5 Therapeutics is headquartered in Dortmund, Germany.
Qli5 Therapeutics develops a new class of proteasome inhibitors.
Qli5 Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Qli5 Therapeutics — Funding & Investors." VCBacked, January 15, 2026, https://www.vcbacked.co/company/qli5-therapeutics. Accessed August 16, 2026.
VCBacked. (2026). Qli5 Therapeutics — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/qli5-therapeutics
{{cite web |title=Qli5 Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/qli5-therapeutics |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated